BNTX Quote, Financials, Valuation and Earnings

Evaxion AS has a net margin of -1.89% compared to BioNTech SE's net margin of -64.14%. BioNTech SE's return on equity of -3.01% beat Evaxion AS's return on equity of --.

BioNTech SE has a consensus price target of $137.68, signalling upside risk potential of 43.41%. On the other hand Evaxion AS has an analysts' consensus of $14.18 which suggests that it could grow by 167.96%. Given that Evaxion AS has higher upside potential than BioNTech SE, analysts believe Evaxion AS is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.295, which suggesting that the stock is 29.477% more volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.8B, which are larger than Evaxion AS quarterly revenues of $37.5K. BioNTech SE's net income of -$33.5M is lower than Evaxion AS's net income of -$4.9M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 6.53x versus 3.55x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -1.89% compared to BioNTech SE's net margin of -19.69%. BioNTech SE's return on equity of -3.01% beat Moderna, Inc.'s return on equity of -30.18%.

BioNTech SE has a consensus price target of $137.68, signalling upside risk potential of 43.41%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that BioNTech SE has higher upside potential than Moderna, Inc., analysts believe BioNTech SE is more attractive than Moderna, Inc..

BioNTech SE has a beta of 1.295, which suggesting that the stock is 29.477% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.8B, which are larger than Moderna, Inc. quarterly revenues of $1B. BioNTech SE's net income of -$33.5M is higher than Moderna, Inc.'s net income of -$200M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 6.53x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -1.89% compared to BioNTech SE's net margin of -287.29%. BioNTech SE's return on equity of -3.01% beat Novavax, Inc.'s return on equity of --.

BioNTech SE has a consensus price target of $137.68, signalling upside risk potential of 43.41%. On the other hand Novavax, Inc. has an analysts' consensus of $12.67 which suggests that it could grow by 84.65%. Given that Novavax, Inc. has higher upside potential than BioNTech SE, analysts believe Novavax, Inc. is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.295, which suggesting that the stock is 29.477% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.8B, which are larger than Novavax, Inc. quarterly revenues of $70.4M. BioNTech SE's net income of -$33.5M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Novavax, Inc.'s PE ratio is 3.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 6.53x versus 1.09x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -1.89% compared to BioNTech SE's net margin of 21.32%. BioNTech SE's return on equity of -3.01% beat Pfizer Inc.'s return on equity of 10.84%.

BioNTech SE has a consensus price target of $137.68, signalling upside risk potential of 43.41%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that BioNTech SE has higher upside potential than Pfizer Inc., analysts believe BioNTech SE is more attractive than Pfizer Inc..

BioNTech SE has a beta of 1.295, which suggesting that the stock is 29.477% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. BioNTech SE pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.8B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. BioNTech SE's net income of -$33.5M is lower than Pfizer Inc.'s net income of $3.6B. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 6.53x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.